[ad_1]
Pfizer pharmaceutical titanium (PFE) – Get the report said there was “no data” to show that a single dose of his covid vaccine provides protection against infection beyond 21 days, according to a media report.
Pfizer told Axios that some protection appears to start as early as 12 days after the first dose.
But the New York health giant also said two doses of the vaccine, three weeks apart, was the only treatment shown to be 95% effective in Phase 3 trials, Axios reports.
He said it was important because the UK’s National Health Service announced a change in its vaccine approach “to give as many people in risk groups their first dose, rather than providing both doses. required in as short a time as possible. “
The NHS said: “Everyone will always get their second dose, and it will be within 12 weeks of their first. The second dose completes the course and is important for long-term protection.”
Pfizer shares recently traded at $ 36.44, down 0.8%. They have slipped 1.8% this year as investors are not seeing its finances benefit much from the vaccine.
Morningstar analyst Damien Conover sees the stock as a bit undervalued, putting the fair value at $ 40.
“We believe that the incredible speed of getting the vaccine to market strengthens [the] innovative power behind Pfizer’s broad moat, ”he wrote this month.
But “we expect strong vaccine competition from ‘other companies’, which is likely to significantly stem the pandemic, but also reduce the profitability of the covid-19 vaccine market,” Conover said.
“We expect the pricing power of vaccines to be weak with so many potential competitors.”
[ad_2]
Source link